Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 7/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 7/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6730242 | 0.91 | S1PR1 (0.45) | RPS6KA3CYP17A1CYP11B1CYP11B2PTGS2 | |
| SCHEMBL6725964 | 0.88 | RPS6KA3 (0.45) | RPS6KA3CYP11B1CYP11B2PTGS2 | |
| SCHEMBL6722648 | 0.88 | RPS6KA3 (0.45) | RPS6KA3CYP17A1PTGS2 | |
| SCHEMBL6725948 | 0.86 | RPS6KA3 (0.46) | RPS6KA3CYP17A1PTGS2 | |
| SCHEMBL6718677 | 0.84 | PTGS2 (0.44) | RPS6KA3CYP17A1PTGS2 | |
| SCHEMBL6728858 | 0.84 | RPS6KA3 (0.43) | RPS6KA3CYP17A1PTGS2 | |
| SCHEMBL6718921 | 0.84 | RPS6KA3 (0.39) | RPS6KA3CYP17A1PTGS2AAK1 | |
| SCHEMBL6723467 | 0.84 | SLC22A12 (0.47) | RPS6KA3KIF11GPBAR1 | |
| SCHEMBL6723317 | 0.84 | RPS6KA3 (0.59) | RPS6KA3PTGS2 | |
| SCHEMBL6729507 | 0.83 | RPS6KA3 (0.51) | RPS6KA3PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, PTGES2, FPR1 | RPS6KA3 972/4885CYP17A1 800/4885CYP11B1 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.